Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions

Circulation

Volumn 102, Issue 1, 2000, Pages 28-34

  Cura, Fernando A ^a   Bhatt, Deepak L ^a   Lincoff, A Michael ^a   Kapadia, Samir R ^a   L'Allier, Philippe L ^a   Ziada, Khaled M ^a   Wolski, Katherine E ^a   Moliterno, David J ^a   Brener, Sorin J ^a   Ellis, Stephen G ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angioplasty; Inhibitors; Lesion; Platelets; Stents

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0034604246     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.1.28     Document Type: Article

References (29)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med. 1994; 331:489-495.
3. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II pilot study. Circulation. 1996;93:412-422.
4. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352: 673-681.
5. Hong MK, Popma JJ, Baim DS, et al. Frequency and predictors of major in-hospital ischemic complications after planned and unplanned new-device angioplasty from the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol. 1997;80:40K-49K.
6. Kastrati A, Schomig A, Elezi S, et al. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. Circulation. 1998;97:2396-2401.
7. Zaacks SM, Allen JE, Calvin JE, et al. Value of the American College of Cardiology/American Heart Association stenosis morphology classification for coronary interventions in the late 1990s. Am J Cardiol. 1998; 82:43-49.
8. Myler RK, Ryan C, Dunlap R, et al. Dyslipoproteinemias in atherosclerosis, thrombosis and restenosis after coronary angioplasty. J Invasive Cardiol. 1995;7:33-46.
9. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection: Multivessel Angioplasty Prognosis Study. Circulation. 1990;82:1193-1202.
10. Ellis SG, Roubin GS, King SB 3rd, et al. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty. Am J Cardiol. 1989;63:30-34.
11. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
12. Ellis SG, Lincoff AM, Miller D, et al, for the EPIC and EPILOG Investigators. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology: Evaluation of 7E3 for the Prevention of Ischemic Complications: Evaluation of PTCA to Improve Long-Term Outcome With Abciximab GPIIb/IIIa Receptor Blockade. J Am Coll Cardiol. 1998;32:1619-1623.
13. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
14. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet. 1997;349:1429-1435.
15. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87-92.
16. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 1999;341:319-327.
17. Neumann FJ, Schomig A. Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. Semin Interv Cardiol. 1998;3:81-90.
18. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
19. Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial: Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol. 1998;32:28-34.
20. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422-1428.
21. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation. 1997;96:1445-1453.
22. Gawaz M, Ruf A, Neumann FJ, et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost. 1998;80:994-1001.
23. Makkar RR, Litvack F, Eigler NL, et al. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation. 1997;95: 1015-1021.
24. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention: EPIC Investigator Group: Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 1997;278:479-484.
25. Abdelmeguid AE, Ellis SG, Sapp SK, et al. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131:1097-1105.
26. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.
27. Abdelmeguid AE, Topol EJ. The myth of the myocardial "infarctlet" during percutaneous coronary revascularization procedures. Circulation. 1996;94:3369-3375.
28. Kong TQ, Davidson CJ, Meyers SN, et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-466.
29. Popma JJ, Lansky AJ, Yeh W, et al. Reliability of the quantitative angiographic measurements in the New Approaches to Coronary Intervention (NACI) registry: a comparison of clinical site and repeated angiographic core laboratory readings. Am J Cardiol. 1997;80:19K-25K.